RayKnowChina Research Map
Shortlist

Hangzhou

Hangzhou Cancer Hospital

杭州市肿瘤医院

Listed for 6 of the 61 diseases this site covers, from the research papers it led and the trials registered with it as lead sponsor or site.

Research activity in public records, not a rating of care. Whether the hospital can help a particular patient is for the hospital and the treating doctor to say.

No official website checked for this hospital yet.

Getting in touch

Research at Hangzhou Cancer Hospital

Choose a disease to see the papers and trials behind it. Each tile shows papers led, 2021–2025, and papers per year.

Only the 61 diseases this site covers. A disease it is not listed for means this hospital did not meet the listing rule for that disease in these records; it does not mean the hospital does not treat it. Which hospitals are listed

  1. Nasopharyngeal carcinoma鼻咽癌1 paper led
  2. Oesophageal squamous cell carcinoma食管鳞状细胞癌4 papers led
  3. Lung cancer肺癌13 papers led1 open trial led
  4. Pancreatic cancer胰腺癌1 paper led1 open trial led
  5. Retinoblastoma视网膜母细胞瘤1 paper led
  6. Osteosarcoma骨肉瘤0 papers led

Not listed for: Hepatocellular carcinoma, Stomach cancer, Breast cancer, Glioma, Hepatoblastoma, Chordoma, Gastrointestinal stromal tumour, Neuroblastoma, Ewing sarcoma, Multiple myeloma, B-cell acute lymphoblastic leukaemia, Aplastic anaemia, Haemophagocytic lymphohistiocytosis, Lymphoma, Beta thalassaemia, Haemophilia A, Atypical haemolytic uraemic syndrome, Thrombotic thrombocytopenic purpura, Fanconi anaemia, Neuromyelitis optica spectrum disorder, IgG4-related disease, Myasthenia gravis, Moyamoya disease, Wilson disease, Biliary atresia, Coronary heart disease, Congenital heart disease, Scoliosis, Anti-NMDA receptor encephalitis, Takayasu arteritis, Hepatic echinococcosis, Idiopathic pulmonary fibrosis, Lymphangioleiomyomatosis, Amyotrophic lateral sclerosis, Spinal muscular atrophy, Fabry disease, Pompe disease, Duchenne muscular dystrophy, Behçet disease, Alport syndrome, IgA nephropathy, Gaucher disease, Niemann–Pick disease type C, Osteogenesis imperfecta, Primary biliary cholangitis, Primary sclerosing cholangitis, Congenital diaphragmatic hernia, Hirschsprung disease, Inherited epidermolysis bullosa, Hereditary angioedema, Familial adenomatous polyposis, Leber hereditary optic neuropathy, Majeed syndrome, NGLY1 deficiency, ISG15 deficiency.

Cancer

Nasopharyngeal carcinoma

鼻咽癌

Led 1 of the 2,375 English-language PubMed papers on nasopharyngeal carcinoma with an author in mainland China, 2021–2025: 0.04%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

8 hospitals in Hangzhou for nasopharyngeal carcinoma183 hospitals in China for nasopharyngeal carcinoma

No open trial on nasopharyngeal carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesInduction / concurrent chemotherapy

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Cancer

Oesophageal squamous cell carcinoma

食管鳞状细胞癌

Led 4 of the 2,923 English-language PubMed papers on oesophageal squamous cell carcinoma with an author in mainland China, 2021–2025: 0.1%.

Papers led
4
2021–2025
Trials led
4
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 2220212022: 1120222023: 0020232024: 0020242025: 112025

6 hospitals in Hangzhou for oesophageal squamous cell carcinoma192 hospitals in China for oesophageal squamous cell carcinoma

No open trial on oesophageal squamous cell carcinoma lists this hospital on ClinicalTrials.gov on 8 Nov 2026.

The records behind these numbers
ThemesRadiotherapyImmunotherapy
Departments in papersRadiation oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led4
  1. Impacts of combining PD-L1 inhibitor and radiotherapy on the tumour immune microenvironment in a mouse model of esophageal squamous cell carcinoma.2025BMC cancerFree full text
  2. Cancer-associated fibroblasts: An emerging target against esophageal squamous cell carcinoma.2022Cancer letters
  3. The mechanisms and reversal strategies of tumor radioresistance in esophageal squamous cell carcinoma.2021Journal of cancer research and clinical oncologyFree full text
  4. CYP2C9 inhibits the invasion and migration of esophageal squamous cell carcinoma via downregulation of HDAC.2021Molecular and cellular biochemistry
All its trials on ClinicalTrials.gov, any status6
  1. CCRT With Itraconazole in Locally Advanced Squamous Esophageal CancerStatus unknownNCT04481100Lead sponsorPhase 2Start 2020-10
  2. Neoadjuvant Anti-PD-1 Antibody SHR-1210 and Radiation in Resectable Esophageal Squamous Cell CarcinomaStatus unknownNCT03200691Lead sponsorPhase 2Start 2017-08
  3. PD-1 Knockout Engineered T Cells for Advanced Esophageal CancerCompletedNCT03081715Lead sponsorN/AStart 2017-03
  4. Combination of Radiation Therapy and Anti-PD-1 Antibody SHR-1210 in Treating Patients With Esophageal CancerCompletedNCT03187314Lead sponsorPhase 2Start 2017-06
  5. Anti-PD-1 Monoclonal Antibody Tislelizumab (BGB-A317) Combined With or Without Anti-TIGIT Monoclonal Antibody Ociperlimab (BGB-A1217) in Participants With Recurrent or Metastatic Esophageal Squamous Cell CarcinomaCompletedNCT04732494Study sitePhase 2Start 2021-03
  6. A Study to Investigate Tislelizumab (BGB-A317) Versus Placebo in Combination With Concurrent Chemoradiotherapy in Participants With Localized Esophageal Squamous Cell CarcinomaCompletedNCT03957590Study sitePhase 3Start 2019-06
More papers found outside PubMed (not counted)8
  1. 2348P High-throughput screening reveals GSK1838705A as a potent inhibitor of CAFs-promoted tumor progression in esophageal squamous cell carcinoma2023Annals of Oncologyarticle
  2. Radiotherapy Combined with PD-L1 Antibody Exerts a Synergistic Anti-tumor Effect in a Mouse Model of Esophageal Squamous Cell Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  3. The Role of Esophagography in the Diagnosis of Orthotopic Esophageal Squamous Cell Carcinoma in a Mouse Mode2023International Journal of Radiation Oncology*Biology*Physicsarticle
  4. Up-Regulation of TCF21 Expression Reverses the Malignant Phenotype of Cancer-Associated Fibroblasts in Esophageal Squamous Cell Carcinoma2023International Journal of Radiation Oncology*Biology*Physicsarticle
  5. Cancer-associated fibroblasts induce epithelial-mesenchymal transition of esophageal squamous cell carcinoma through paracrine TGFβ1 signalling2022Research Squarepreprint
  6. Epigenetically inhibiting CYP3A5 modulates the migration and invasion of esophageal squamous cell carcinoma via ZEB22022Research Squarepreprint
  7. Postoperative Radiotherapy Involving Tumor Bed with or without Elective Nodal Irradiation in Patients with Locally Advanced Esophageal Squamous Cell Carcinoma: A Multi-Center, Prospective Randomized Phase II Trial2022International Journal of Radiation Oncology*Biology*Physicsarticle
  8. P14.15 Circulating Tumor DNA Predict the Response and Survival after Tislelizumab Immunotherapy for Advanced Esophageal Squamous Cell Carcinoma2021Journal of Thoracic Oncologyconference-abstract

Run the PubMed searchClinicalTrials.gov

Cancer

Lung cancer

肺癌

Led 13 of the 23,356 English-language PubMed papers on lung cancer with an author in mainland China, 2021–2025: 0.06%.

Papers led
13
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
1
led by another institution
Papers led per year
2021: 6620212022: 4420222023: 1120232024: 0020242025: 222025

11 hospitals in Hangzhou for lung cancer251 hospitals in China for lung cancer

Open trials with this hospital 2

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07875465

    Age 18 years to Not stated (registered criteria)

    Led by Hangzhou Cancer HospitalHangzhou

  2. Recruiting
    Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLC
    Phase
    Phase 2
    Started
    2024-04
    Posted
    Registry
    NCT06718309

    Age 18 years to Not stated (registered criteria)

    Lead sponsor is not a listed hospital; 1 listed hospital as study siteHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncologyRadiation oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led13
  1. Bevacizumab reduces PD-L1 Not PD-1 inhibitor-associated pneumonitis in non-small cell lung cancer patients.2025Cancer immunology, immunotherapy : CIIFree full text
  2. Combination of anlotinib and irinotecan as second-line therapy in extensive-stage small-cell lung cancer relapsed within six months: a single-arm phase Ⅱ study.2025Lung cancer (Amsterdam, Netherlands)
  3. Cancer-associated fibroblasts facilitate DNA damage repair by promoting the glycolysis in non-small cell lung cancer.2023Biochimica et biophysica acta. Molecular basis of disease
  4. Valtrate antagonizes malignant phenotypes of lung cancer cells by reducing SLC7A11.2022Human & experimental toxicology
  5. The mechanism of Bai He Gu Jin Tang against non-small cell lung cancer revealed by network pharmacology and molecular docking.2022MedicineFree full text
  6. Postoperative radiotherapy for patients with completely resected stage IIIA-N2 non-small cell lung cancer: opt-in or opt-out.2022Thoracic cancerFree full text
  7. Blood exosome PD-L1 is associated with PD-L1 expression measured by immunohistochemistry, and lymph node metastasis in lung cancer.2022Tissue & cell
  8. Effect of continuous nursing based on the Omaha System on cancer-related fatigue in patients with lung cancer undergoing chemotherapy: a randomized controlled trial.2021Annals of palliative medicineRCT
  9. Thoracic radiotherapy and concurrent almonertinib for unresectable stage III EGFR-mutated non-small-cell lung cancer: a phase 2 study.2021BMC cancerFree full text
  10. Cancer-associated fibroblasts in non-small cell lung cancer: Recent advances and future perspectives.2021Cancer letters
  11. Curcumin suppresses tumor growth of gemcitabine-resistant non-small cell lung cancer by regulating lncRNA-MEG3 and PTEN signaling.2021Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico
  12. MiR-221-3p-mediated downregulation of MDM2 reverses the paclitaxel resistance of non-small cell lung cancer in vitro and in vivo.2021European journal of pharmacology
  13. Suberoylanilide hydroxamic acid enhances the radiosensitivity of lung cancer cells through acetylated wild-type and mutant p53-dependent modulation of mitochondrial apoptosis.2021The Journal of international medical researchFree full text
Chinese-language papers (not in the count)1
  1. [Advances in Predictive Research of Immune Checkpoint Inhibitors-related 
Adverse Events].2023Zhongguo fei ai za zhi = Chinese journal of lung cancerFree full text
All its trials on ClinicalTrials.gov, any status19
  1. RT Plus EGFR-TKI for Wild-type NSCLCStatus unknownNCT02738983Lead sponsorPhase 2Start 2012-01
  2. Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver MetastasesNot yet recruitingNCT07875465Lead (inferred)Phase 2Start 2026-10
  3. Chemotherapy Plus Immunotherapy Combined With SBRT as Neoadjuvant Therapy for Patients With Resectable NSCLCRecruitingNCT06718309Study sitePhase 2Start 2024-04
  4. A Trial of Camrelizumab Combined With Famitinib Malate in Treatment Naïve Subjects With PD-L1-Positive Recurrent or Metastatic Non-Small Cell Lung CancerStatus unknownNCT05042375Study sitePhase 3Start 2022-09
  5. Study of Pembrolizumab/Vibostolimab (MK-7684A) in Combination With Concurrent Chemoradiotherapy Followed by Pembrolizumab/Vibostolimab Versus Concurrent Chemoradiotherapy Followed by Durvalumab in Participants With Stage III Non-small Cell Lung Cancer (MK-7684A-006)CompletedNCT05298423Study sitePhase 3Start 2022-05
  6. AP-L1898 Capsule in Patients With Non-small Cell Lung CancerTerminatedNCT04993391Study sitePhase 1/Phase 2Start 2021-07
  7. Camrelizumab Combined With SRT/WBRT and Chemotherapy in Patients With Brain Metastases of Driven Gene-negative NSCLCCompletedNCT04768075Study sitePhase 3Start 2021-05
  8. Coformulation of Pembrolizumab/Vibostolimab (MK-7684A) Versus Pembrolizumab (MK-3475) Monotherapy for Programmed Cell Death 1 Ligand 1 (PD-L1) Positive Metastatic Non-Small Cell Lung Cancer (MK-7684A-003, KEYVIBE-003)TerminatedNCT04738487Study sitePhase 3Start 2021-04
  9. A Study of Atezolizumab and Tiragolumab Compared With Durvalumab in Participants With Locally Advanced, Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)CompletedNCT04513925Study sitePhase 3Start 2020-08
  10. SBRT Combined With PD-1 Inhibitor and Thoracic Hyperthermia for Advanced NSCLCStatus unknownNCT05520853Study sitePhase 2Start 2020-01
  11. Platinum-Based Chemotherapy With/Without INCMGA00012, an Anti-PD-1 Antibody, in Non-Small Cell Lung CancerCompletedNCT04205812Study sitePhase 3Start 2020-09
  12. HX008 Plus Chemotherapy VS Pembrolizumab Plus Chemotherapy As the First-line Treatment in Participants With Advanced or Metastatic Nonsquamous Non-small Cell Lung CancerStatus unknownNCT04750083Study sitePhase 2/Phase 3Start 2020-09
  13. A Phase 2 Trial of Almonertinib With Concurrent Radiotherapy in The Treatment of Local Advanced EGFR-mutant NSCLCStatus unknownNCT04636593Study sitePhase 2Start 2020-08
  14. Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Retrospective StudyStatus unknownNCT04397432Study siteStart 2020-08
  15. Placebo-controlled, Study of Concurrent Chemoradiation Therapy With Pembrolizumab Followed by Pembrolizumab and Olaparib in Newly Diagnosed Treatment-Naïve Limited-Stage Small Cell Lung Cancer (LS-SCLC) (MK 7339-013/KEYLYNK-013)Active, not recruitingNCT04624204Study sitePhase 3Start 2020-12
  16. Synergistic Effect of Elemene Plus TKIs Compared With TKIs in EGFR-mutated Advanced NSCLC:Prospective StudyStatus unknownNCT04401059Study sitePhase 4Start 2020-11
  17. A Phase II Trial of Upfront Radiotherapy Plus Almonertinib for Epidermal Growth Factor Receptor(EGFR)-Mutant Non-small-cell Lung Cancer(NSCLC) Patients With Brain MetastasesStatus unknownNCT04643847Study sitePhase 2Start 2020-11
  18. A Single-arm, Phase Ⅱ Clinical Trial of Anlotinib Hydrochloride Combined With Irinotecan or Docetaxel for Second Line Treatment of Nonsensitive Relapsed Small-cell Lung CancerStatus unknownNCT04757779Study sitePhase 2Start 2019-12
  19. Concurrent Nab-P/Carboplatin and Thoracic Radiotherapy in Squamous Cell Lung CancerStatus unknownNCT01494415Study sitePhase 2Start 2012-07

Run the PubMed searchClinicalTrials.gov

Cancer

Pancreatic cancer

胰腺癌

Led 1 of the 5,743 English-language PubMed papers on pancreatic cancer with an author in mainland China, 2021–2025: 0.02%.

Papers led
1
2021–2025
Trials led
2
any status, ClinicalTrials.gov
Open trials led
1
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 1120212022: 0020222023: 0020232024: 0020242025: 002025

9 hospitals in Hangzhou for pancreatic cancer192 hospitals in China for pancreatic cancer

Open trials with this hospital 1

Recruiting, not yet recruiting, or by invitation on ClinicalTrials.gov on 18 Nov 2026. Trials registered only in China’s own registry (ChiCTR) are not included. Whether someone can take part is decided by the study team.

  1. Not yet recruiting
    Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver Metastases
    Phase
    Phase 2
    Started
    2026-10
    Posted
    Registry
    NCT07875465

    Age 18 years to Not stated (registered criteria)

    Led by Hangzhou Cancer HospitalHangzhou

Open in the full trial list

Order: recruiting first, then not yet recruiting and by invitation; newest start first. Not a ranking.

The records behind these numbers
Departments in papersMedical oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. Association Studies of ERCC2 rs13181 Polymorphism with Pancreatic Cancer Susceptibility.2021Critical reviews in eukaryotic gene expression
All its trials on ClinicalTrials.gov, any status2
  1. Intestinal Low-Dose Radiotherapy Combined With Immune Checkpoint Inhibitors in Solid Tumors With Liver MetastasesNot yet recruitingNCT07875465Lead (inferred)Phase 2Start 2026-10
  2. Combination of Radiation Therapy and Anti-PD-1 Antibody in Treating Patients With Pancreatic CancerStatus unknownNCT03374293Lead (inferred)Phase 2Start 2017-12

Run the PubMed searchClinicalTrials.gov

Cancer

Retinoblastoma

视网膜母细胞瘤

Led 1 of the 301 English-language PubMed papers on retinoblastoma with an author in mainland China, 2021–2025: 0.3%.

Papers led
1
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution
Papers led per year
2021: 0020212022: 0020222023: 0020232024: 1120242025: 002025

5 hospitals in Hangzhou for retinoblastoma176 hospitals in China for retinoblastoma

No open trial on retinoblastoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers
Departments in papersRadiation oncology

Hospital name read automatically from author addresses, not yet checked by hand.

Papers it led1
  1. A meta-analysis of the efficacy of intra-arterial chemotherapy for the management of retinoblastoma patients.2024Advances in clinical and experimental medicine : official organ Wroclaw Medical University

Run the PubMed searchClinicalTrials.gov

Cancer

Osteosarcoma

骨肉瘤

Led no English-language PubMed papers on osteosarcoma in 2021–2025. Its linked research records are below.

Papers led
0
2021–2025
Trials led
0
any status, ClinicalTrials.gov
Open trials led
0
recruiting or about to
Open trials as a site
0
led by another institution

20 hospitals in Hangzhou for osteosarcoma570 hospitals in China for osteosarcoma

No open trial on osteosarcoma lists this hospital on ClinicalTrials.gov on 13 Nov 2026.

The records behind these numbers

Hospital name read automatically from author addresses, not yet checked by hand.

Run the PubMed searchClinicalTrials.gov

Getting in touch

Name card to show staff or a driver

杭州市肿瘤医院

Hangzhou Cancer Hospital

杭州

Large hospitals often have several campuses. Confirm the campus with the hospital before travelling.

Inquiry letter in English and Chinese

Fill in the brackets, then send it through the contact options on the hospital's international office or official website. Nothing typed here leaves this device.

Records hospitals usually ask for

  • A recent summary or letter from the treating doctor
  • Pathology report
  • Scans (CT, MRI, PET) with their reports, and the images if possible
  • Treatments so far, with dates
  • Current medicines

What to do next

Talk with the treating doctorThis page can be shared with the treating doctor to discuss whether this team's work is relevant.
Check the team is still therePapers lag by months and doctors move. Look for the department on the hospital's own website.
Contact the hospital directlyUse the hospital's own contacts. Hospitals never pay us, and each hospital decides which patients it accepts.

Where these numbers come from

Papers

English-language PubMed papers whose first or last author lists this hospital as their first affiliation, 2021–2025. Definitions

Trials

ClinicalTrials.gov records naming this hospital as lead sponsor or site, as of 8 Nov 2026.

Identifiers and other names

ROR

Suggest a correctionDownload the data